Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management (TICA KOREA)
A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Dae-jeon, Korea, Republic of
- Chungnam National University Hospital
-
Daegu, Korea, Republic of
- Keimyung University Dongsan Medical Center
-
Gyeongju, Korea, Republic of
- Dongguk University Gyeongju Hospital
-
Ilsan, Korea, Republic of
- Inje University Ilsan Paik Hospital
-
Incheon, Korea, Republic of
- Gachon University Gil Hospital
-
Jeonju, Korea, Republic of
- Chonbuk National University Hospital
-
Pusan, Korea, Republic of
- Inje University Pusan Paik Hospital
-
Pusan, Korea, Republic of
- Dong-A Medical Center
-
Ulsan, Korea, Republic of
- Ulsan University Hospital
-
-
Songpa-gu
-
Seoul, Songpa-gu, Korea, Republic of, 138-736
- Asan Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 and more
- Index event of non-ST or ST segment elevation ACS
- Provision of signed informed consent
Exclusion Criteria:
- Hypersensitivity to aspirin or ticagrelor
- Oral anticoagulation therapy that cannot be stopped
- Treated with thrombolysis within 24hrs
- Any other reason the investigator deems the subject to be unsuitable for the study e.g., Active malignant tumor
- Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic index, or strong CYP3A inducers
- Any life-threatening condition with life expectancy less than 6months
- Mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study
- High risk due to malignant hypertension
- The conditions associated with increased risk of bradycardiac events
- Subjects with severe liver disease
- Subjects requiring dialysis
- Increased bleeding risk
- History of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days
- Thrombocytopenia or leukopenia
- Positive pregnancy test or is known to be pregnant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Clopidogrel
|
600mg loading and 75mg qd
|
|
Experimental: Ticagrelor
|
180mg loading and 90mg bid
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The time to first occurrence of any bleeding event
Time Frame: 1year
|
Safety of Ticagrelor compared to Clopidogrel by measuring the time to first occurrence of any bleeding event(including major, minor bleedings)
|
1year
|
|
The time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke
Time Frame: 1year
|
Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of any event from the composite of death from vascular causes, Myocardial Infarction (MI) and stroke
|
1year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The time to first occurrence of major bleeding event
Time Frame: 1year
|
by PLAtelet inhibition and patient Outcomes(PLATO) criteria
|
1year
|
|
The time to first occurrence of minor bleeding event
Time Frame: 1year
|
by PLAtelet inhibition and patient Outcomes(PLATO) criteria
|
1year
|
|
The time to first occurrence of major bleeding event or minor bleeding event
Time Frame: 1year
|
The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria
|
1year
|
|
The time to first occurrence of major bleeding event
Time Frame: 1year
|
The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria
|
1year
|
|
The time to first occurrence of minor bleeding event
Time Frame: 1year
|
The Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria
|
1year
|
|
The time to first occurrence of Bleeding Academic Research Consortium (BARC) bleeding event from type 1 to type 5
Time Frame: 1year
|
By Bleeding Academic Research Consortium(BARC) Definition of Bleeding Events
|
1year
|
|
The time of first occurrence of discontinuation of study medication from any bleeding event
Time Frame: 1year
|
1year
|
|
|
Non serious adverse events
Time Frame: 1year
|
1year
|
|
|
Adverse events following discontinuation of study medication
Time Frame: 1year
|
1year
|
|
|
Serious adverse events
Time Frame: 1year
|
1year
|
|
|
The time to first occurrence of death from vascular causes
Time Frame: 1year
|
Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of death from vascular causes
|
1year
|
|
The time to first occurrence of myocardial infarction
Time Frame: 1year
|
Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of myocardial infarction
|
1year
|
|
The time to first occurrence of stroke
Time Frame: 1year
|
Effect of Ticagrelor compared to Clopidogrel by measuring: time to first occurrence of stroke
|
1year
|
|
The time to occurrence of composite events
Time Frame: 1year
|
The time to occurrence of composite events(death from any cause, myocardial infarction, stroke)
|
1year
|
|
The time to occurrence of death from any cause
Time Frame: 1year
|
1year
|
|
|
Number of patients with net clinical benefit of any total bleeding and any event from the composite of death from vascular causes, Myocardial Infarction and stroke.
Time Frame: 1year
|
1year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Vascular Diseases
- Pain
- Neurologic Manifestations
- Disease
- Chest Pain
- Heart Diseases
- Myocardial Ischemia
- Cardiovascular Diseases
- Syndrome
- Ischemia
- Acute Coronary Syndrome
- Angina Pectoris
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Ticagrelor
- Clopidogrel
Other Study ID Numbers
Other Study ID Numbers
- AMCCV2013-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.